The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension

Therapeutic Advances in Respiratory Disease

Volumn 8, Issue 3, 2014, Pages 84-92

  Steriade, Alexandru ^a,b   Seferian, Andrei ^a,b   Jaïs, Xavier ^a,b   Savale, Laurent ^a,b   Jutant, Etienne Marie ^a,b   Parent, Florence ^a,b   Sitbon, Olivier ^a,b   Humbert, Marc ^a,b   Simonneau, Gerald ^a,b   Montani, David ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

Endothelin; endothelin receptor antagonist; macitentan; pulmonary arterial hypertension; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; MACITENTAN; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOPULMONARY HEMODYNAMICS; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG WITHDRAWAL; EDEMA; EUROPEAN MEDICINES AGENCY; EXERCISE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; LONG TERM CARE; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 84904645303     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465814530182     Document Type: Review

References (38)

1. Atsmon J. Dingemanse J. Shaikevich D. Volokhov I. Sidharta P. (2013) Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 52: 685–692.
2. Battistini B. Berthiaume N. Kelland N. Webb D. Kohan D. (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the novel ‘-sentan— class of drug. Exp Biol Med 231: 653–695.
3. Berti F. Rossoni G. Della Bella D. Villa L. Buschi A. Trento F. (1993) Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 22: 321–326.
4. Bolli M.H. Boss C. Binkert C. Buchmann S. Bur D. Hess P. (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N—-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55: 7849–7861.
5. Bruderer S. Aånismaa P. Homery M.-C. Håusler S. Landskroner K. Sidharta P. (2012a) Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 14: 68–78.
6. Bruderer S. Hopfgartner G. Seiberling M. Wank J. Sidharta P. Treiber A. (2012b) Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica Fate Foreign Compd Biol Syst 42: 901–910.
7. Bruderer S. Marjason J. Sidharta P. Dingemanse J. (2013) Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology 91: 331–338.
8. Clozel M. (2006) Actelion-1 ’ first tissue-targeting endothelin receptor antagonist ’ in phase III for pulmonary hypertension (PH). Media release, 11 December 2006, Actelion, Basle, Switzerland, available at http://www1.actelion.com/en/investors/media-releases/index.page?newsId=1203999.
9. Dupuis J. Hoeper M. (2008) Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31: 407–415.
10. Dupuis J. Prié S. (1999) The ET(A)-receptor antagonist LU 135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats. J Cardiovasc Pharmacol Ther 4: 33–39.
11. Dupuis J. Stewart D. Cernacek P. Gosselin G. (1996) Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 1578–1584.
12. Filep J. Bodolay E. Sipka S. Gyimesi E. Csipö I. Szegedi G. (1995) Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 92: 2969–2974.
13. Fukuroda T. Fujikawa T. Ozaki S. Ishikawa K. Yano M. Nishikibe M. (1994) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199: 1461–1465.
14. Galiè N. Corris P. Frost A. Girgis R. Granton J. Jing Z. (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(25 Suppl.): doi:10.1016/j.jacc.2013.10.031
15. Galiè N. Humbert M. Torbicki A. Vachiery J. Barbera J. Beghetti M. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219–1263.
16. Gatfield J. Mueller Grandjean C. Sasse T. Clozel M. Nayler O. (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PloS One 7: e47662.
17. Giaid A. Yanagisawa M. Langleben D. Michel R. Levy R. Shennib H. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739.
18. Hirata Y. Emori T. Eguchi S. Kanno K. Imai T. Ohta K. (1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367–1373.
19. Iglarz M. Binkert C. Morrison K. Fischli W. Gatfield J. Treiber A. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327: 736–745.
20. Juergens U. Racké K. Uen S. Haag S. Lamyel F. Stöber M. (2008) Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther 21: 533–539.
21. Kummer O. Haschke M. Hammann F. Bodmer M. Bruderer S. Regnault Y. (2009) Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci 38: 384–388.
22. Lavelle A. Sugrue R. Lawler G. Mulligan N. Kelleher B. Murphy D. (2009) Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 34: 770–771.
23. Ortega Mateo A. de Artiñano A. (1997) Highlights on endothelins: a review. Pharmacol Res 36: 339–351.
24. Pollock DM. (2005) Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 45: 477–480. doi:10.1161/01.HYP.0000158262.11935.d0
25. Pollock D. Boesen E. Black S. (2009). Does targeting the lipophilic milieu provide advantages for an endothelin antagonist? Mol Interv 9: 75–78.
26. Prié S. Leung T. Cernacek P. Ryan J. Dupuis J. (1997) The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 282: 1312–1318.
27. Prié S. Stewart D. Dupuis J. (1998) EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation 97: 2169–2174.
28. Pulido T. Adzerikho I. Channick R. Delcroix M. Galiè N. Ghofrani H. (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369: 809–818.
29. Raja S. (2010) Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. Cardiovasc Ther 28: e65–71.
30. Raja S. Dreyfus G. (2008) Current status of bosentan for treatment of pulmonary hypertension. Ann Card Anaesth 11: 6–14.
31. Rubens C. Ewert R. Halank M. Wensel R. Orzechowski H. Schultheiss H. (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest J 120: 1562–1569.
32. Rubin L. Dufton C. Gerber M. (2005) Ambrisentan for pulmonary arterial hypertension. Future Cardiol 1: 425–432.
33. Sidharta P. Lindegger N. van Giersbergen P. Dingemanse J. (2012) Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new endothelin receptor antagonist, in subjects with mild, moderate or severe hepatic impairment. Chest 142: 826A.
34. Sidharta P. van Giersbergen P. Dingemanse J. (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol 53: 1131–1138.
35. Sidharta P. van Giersbergen P. Halabi A. Dingemanse J. (2011) Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 67: 977–984.
36. Simonneau G. Robbins I. Beghetti M. Channick R. Delcroix M. Denton C. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43–54.
37. Wenzel R. Fleisch M. Shaw S. Noll G. Kaufmann U. Schmitt R. (1998) Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98: 2235–2240.
38. Yu J. Taylor L. Wilson J. Comhair S. Erzurum S. Polgar P. (2013). Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension. J Cell Physiol 228: 322–329.